Equillium, Inc. (EQ )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol EQ
- Company Equillium, Inc.
- Price $1.04
- Changes Percentage 1.44
- Change 0.015
- Day Low $1.03
- Day High $1.14
- Year High $2.35
- Year Low $0.27
- Market Cap $36,942,317
- Price Avg 50 EMA (D) $1.41
- Price Avg 200 EMA (D) $0.84
- Exchange NASDAQ
- Volume 310,596
- Average Volume 1,315,554
- Open $1.07
- Previous Close $1.04
- EPS -0.57
- PE -1.82
- Earnings Announcement 2026-03-26 04:00:00
- Shares Outstanding $35,521,459
Company brief: EQUILLIUM, INC. (EQ )
- Healthcare
- Biotechnology
- Mr. Bruce D. Steel C.F.A.
- https://equilliumbio.com
- US
- N/A
- 10-12-2018
- US29446K1060
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.